SAB Biotherapeutics (SABS) Institutional Ownership $3.01 -0.05 (-1.63%) (As of 12:50 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for SAB Biotherapeutics (NASDAQ:SABS)CurrentInstitutional OwnershipPercentage7.82%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$13.99MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$37.86M Get SABS Insider Trade Alerts Want to know when executives and insiders are buying or selling SAB Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SABS Institutional Buying and Selling by Quarter Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide SAB Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2024 Kovitz Investment Group Partners LLC19,201$52K0.0%N/A0.208% 11/15/2024 RTW Investments LP635,276$1.72M0.0%-17.2%6.883% 7/17/2024 First PREMIER Bank19,386$60K0.0%N/A0.210% 5/16/2024 BVF Inc. IL917,826$4.17M0.1%-90.0%9.944% 2/15/2024 BVF Inc. IL9,178,282$6.31M0.2%N/A175.426% 2/14/2024 Commodore Capital LP1,831,746$1.26M0.1%N/A35.024% Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/14/2024 RTW Investments LP9,178,282$6.31M0.1%N/A175.493% 11/8/2023Pathstone Family Office LLC506,513$319K0.0%N/A0.968% 8/9/2023Institutional & Family Asset Management LLC192,027$159K0.0%+28.2%0.381% 2/2/2023 Silver Oak Securities Incorporated51,941$31K0.0%N/A0.121% 11/7/2022Institutional & Family Asset Management LLC149,774$105K0.0%+91.7%0.348% 10/20/2022 First PREMIER Bank807,535$566K0.2%+23.8%1.877% 8/15/2022 LGL Partners LLC23,000$33K0.0%N/A0.054% 8/3/2022 AE Wealth Management LLC18,700$27K0.0%N/A0.044% 7/26/2022 First PREMIER Bank652,440$946K0.3%N/A1.519% 5/9/2022 Qube Research & Technologies Ltd24,179$91K0.0%+43.8%0.056% 2/14/2022 Radcliffe Capital Management L.P.546,658$5.52M0.1%N/A1.257% 2/14/2022ETF Managers Group LLC13,202$105K0.0%N/A0.030% 2/14/2022Institutional & Family Asset Management LLC78,115$610K0.1%N/A0.180% 2/10/2022 Qube Research & Technologies Ltd16,817$131K0.0%N/A0.039% 2/9/2022 Wolverine Asset Management LLC6,602$51K0.0%N/A0.015% 2/9/2022 Alps Advisors Inc.50,306$393K0.0%N/A0.116% 2/3/2022Spectrum Management Group LLC5,030$39K0.0%N/A0.012% 2/1/2022 Qube Research & Technologies Ltd16,817$131K0.0%N/A0.039% 1/19/2022 First PREMIER Bank832,555$6.50M1.7%N/A1.915% 1/18/2022 Nadler Financial Group Inc.11,000$86K0.0%N/A0.025% 11/17/2021 Tudor Investment Corp Et Al60,000$605K0.0%N/A0.406% (Data available from 1/1/2016 forward) SABS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SABS shares? During the previous two years, the following institutional investors and hedge funds held shares of SAB Biotherapeutics shares: BVF Inc. IL ($4.17M), RTW Investments LP ($1.72M), Commodore Capital LP ($1.26M), Pathstone Family Office LLC ($319K), Institutional & Family Asset Management LLC ($159K), First PREMIER Bank ($60K), and Kovitz Investment Group Partners LLC ($52K).Learn more on SABS's institutional investors. What percentage of SAB Biotherapeutics stock is owned by institutional investors? 7.82% of SAB Biotherapeutics stock is owned by institutional investors. Learn more on SABS's institutional investor holdings. Which institutional investors have been buying SAB Biotherapeutics stock? The following institutional investors have purchased SAB Biotherapeutics stock in the last 24 months: BVF Inc. IL ($9.18M), RTW Investments LP ($9.18M), Commodore Capital LP ($1.83M), Pathstone Family Office LLC ($506.51K), Silver Oak Securities Incorporated ($51.94K), Institutional & Family Asset Management LLC ($42.25K), and First PREMIER Bank ($19.39K). How much institutional buying is happening at SAB Biotherapeutics? Institutional investors have bought a total of 20,827,604 shares in the last 24 months. This purchase volume represents approximately $14.38M in transactions. Which SAB Biotherapeutics major shareholders have been selling company stock? The following institutional investors have sold SAB Biotherapeutics stock in the last 24 months: BVF Inc. IL ($8.26M), and RTW Investments LP ($131.67K). How much institutional selling is happening at SAB Biotherapeutics? Institutional investors have sold a total of 8,392,126 shares in the last 24 months. This volume of shares sold represents approximately $37.86M in transactions. Related Companies RGLS Institutional Ownership AGEN Institutional Ownership FBIO Institutional Ownership CRIS Institutional Ownership BOLT Institutional Ownership MTEM Institutional Ownership AMGN Institutional Ownership VRTX Institutional Ownership GILD Institutional Ownership REGN Institutional Ownership This page (NASDAQ:SABS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.